Your browser doesn't support javascript.
SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy.
Sun, Lova; Surya, Sanjna; Goodman, Noah G; Le, Anh N; Kelly, Gregory; Owoyemi, Olutosin; Desai, Heena; Zheng, Cathy; DeLuca, Shannon; Good, Madeline L; Hussain, Jasmin; Jeffries, Seth D; Kry, Yolanda R; Kugler, Emily M; Mansour, Maikel; Ndicu, John; Osei-Akoto, AnnaClaire; Prior, Timothy; Pundock, Stacy L; Varughese, Lisa A; Weaver, JoEllen; Doucette, Abigail; Dudek, Scott; Verma, Shefali Setia; Gouma, Sigrid; Weirick, Madison E; McAllister, Christopher M; Bange, Erin; Gabriel, Peter; Ritchie, Marylyn; Rader, Daniel J; Vonderheide, Robert H; Schuchter, Lynn M; Verma, Anurag; Maillard, Ivan; Mamtani, Ronac; Hensley, Scott E; Gross, Robert; Wileyto, E Paul; Huang, Alexander C; Maxwell, Kara N; DeMichele, Angela.
  • Sun L; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Surya S; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Goodman NG; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Le AN; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Kelly G; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Owoyemi O; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Desai H; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Zheng C; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • DeLuca S; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Good ML; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Hussain J; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Jeffries SD; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Kry YR; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Kugler EM; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Mansour M; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Ndicu J; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Osei-Akoto A; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Prior T; Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Pundock SL; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Varughese LA; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Weaver J; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Doucette A; Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Dudek S; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Verma SS; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Gouma S; Department of Microbiology, University of Pennsylvania, Philadelphia, PA.
  • Weirick ME; Department of Microbiology, University of Pennsylvania, Philadelphia, PA.
  • McAllister CM; Department of Microbiology, University of Pennsylvania, Philadelphia, PA.
  • Bange E; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Gabriel P; Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Ritchie M; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Rader DJ; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Vonderheide RH; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Schuchter LM; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Verma A; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Maillard I; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Mamtani R; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Hensley SE; Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Gross R; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Wileyto EP; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Huang AC; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Maxwell KN; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • DeMichele A; Department of Microbiology, University of Pennsylvania, Philadelphia, PA.
JCO Oncol Pract ; 17(12): e1879-e1886, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1270943
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
Semantic information from SemMedBD (by NLM)
1. directive therapy TREATS Patients
Subject
directive therapy
Predicate
TREATS
Object
Patients
2. Antibodies PART_OF 2019 novel coronavirus
Subject
Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
3. Blood NEG_LOCATION_OF Antibodies
Subject
Blood
Predicate
NEG_LOCATION_OF
Object
Antibodies
4. Blood LOCATION_OF Antibodies
Subject
Blood
Predicate
LOCATION_OF
Object
Antibodies
5. Malignant Neoplasms PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
PROCESS_OF
Object
Patients
6. directive therapy TREATS Patients
Subject
directive therapy
Predicate
TREATS
Object
Patients
7. Antibodies PART_OF 2019 novel coronavirus
Subject
Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
8. Blood NEG_LOCATION_OF Antibodies
Subject
Blood
Predicate
NEG_LOCATION_OF
Object
Antibodies
9. Blood LOCATION_OF Antibodies
Subject
Blood
Predicate
LOCATION_OF
Object
Antibodies
10. Malignant Neoplasms PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
PROCESS_OF
Object
Patients
ABSTRACT

PURPOSE:

Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. We aimed to gauge the effectiveness of these measures at the University of Pennsylvania.

METHODS:

We conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between May 21, 2020, and October 8, 2020. Participants completed questionnaires and had up to five serial blood collections.

RESULTS:

Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95% CI, 0.0 TO 4.1%) over 14.8 person-years of follow up, with a median of 13 health care visits per patient.

CONCLUSION:

These results suggest that patients with cancer receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection.

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Observational study Language: English Journal: JCO Oncol Pract Clinical aspect: Prognosis Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Observational study Language: English Journal: JCO Oncol Pract Clinical aspect: Prognosis Year: 2021
...